NYMOX PHARMACEUTICAL CORP (NYMX)

BSP733981026 - Common Stock

0.2  -0.05 (-19.68%)

After market: 0.1767 -0.02 (-11.65%)

Full estimates are only available for subscribed users, you can see which data is available below.

Subscribed users also see more surprise data, now it is restricted to 4 quarters.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2018 2019 2020 2021 2022
Revenue
YoY % growth
300K
36.36%		120K
-60.00%		10K
-91.67%		N/A
-100.00%		N/A
EBITDA
YoY % growth
-10.64M
19.64%		-13.32M
-25.19%		-11.71M
12.09%		N/A
-6.68%		N/A
46.85%
EBIT
YoY % growth
-10.64M
19.64%		-13.33M
-25.28%		-11.72M
12.08%		N/A
-6.69%		N/A
46.80%
Operating Margin
-3,546.67%-11,108.33%-117,200.00%N/AN/A
EPS
YoY % growth
N/AN/AN/AN/AN/A

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
EPS
Q2Q % growth
Revenue
Q2Q % growth
EBITDA
Q2Q % growth
EBIT
Q2Q % growth

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q1 2021
Q2Q % growth
-100.00%		%
Q4 2020
Q2Q % growth
-100.00%		%
Q3 2020
Q2Q % growth
-100.00%		%
Q2 2020
Q2Q % growth
-100.00%		%
Q1 2020
Q2Q % growth		 10K
-66.67%		%
Q4 2019
Q2Q % growth		 30K
50.00%		%
Q3 2019
Q2Q % growth		 40K %
Q2 2019
Q2Q % growth		 20K
-77.78%		%
Q1 2019
Q2Q % growth		 30K
-80.00%		%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPSN/A N/A N/A N/A
RevenueN/A N/A N/A N/A